article thumbnail

FDA fast tracks type 1 diabetes cell therapy from Vertex

pharmaphorum

The therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. If VX-880 works, it could remove or reduce the reliance of patients with the disease on insulin injections. That implantable technology was at the heart of the Semma acquisition.

article thumbnail

Type 1 Diabetes Vaccine: Does Diamyd Have a Winning Formula?

XTalks

In addition to the vaccine, the company is also developing an investigational drug called Remygen for the regeneration of endogenous insulin production and to improve hormonal response to hypoglycemia; trials to test the treatment are currently ongoing in patients that have been living with type 1 diabetes for more than five years.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

COVID-19 May Trigger New-Onset Diabetes

XTalks

While type 2 diabetes is associated with inflammation, which could potentially explain the link between a COVID-19 infection and ensuing inflammatory response, the reasons for the onset of insulin-dependent type I diabetes is a bit less clear.

Insulin 105
article thumbnail

Tzield Gets FDA Nod to Become First Approved Drug to Delay Onset of Type 1 Diabetes

XTalks

Type 1 diabetes, also known as insulin-dependent or juvenile diabetes, is an autoimmune disease that occurs when the body is unable to make enough insulin due to destruction of the beta insulin-producing cells in the pancreas. In the US, it is estimated that 1.45 million people are currently living with type 1 diabetes.

Insulin 97
article thumbnail

Investigating the role of Brd4 in diet-induced obesity

Scienmag

Credit: Lin-Feng Chen A new study, published in JCI Insight, looks at how Brd4, a regulator of the innate immune response, influences diet-induced obesity. The researchers believe that Brd4 could be used as a target for obesity and insulin resistance. Approximately one-third of the adults and one in five children in the U.S.

article thumbnail

Vertex buys diabetes cell therapy rival ViaCyte for $320m

pharmaphorum

Vertex’ therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The first patient treated with the therapy saw their need for insulin reduce to almost zero, helping VX-880 claim a fast-track designation from the FDA.

Insulin 59
article thumbnail

Pharma still reluctant to back gamification for health; interview

pharmaphorum

Sri Prakash describes FriendsLearn’s approach as administering a “digital vaccine” that along with changing habits could induce an immune response through biological pathways of the gut-brain axis – a two-way communication channel linking emotional and cognitive centres of the brain with peripheral intestinal functions.